Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
Recruiting
Phase 2
Interventional Study
Heart Failure
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 40 – 85
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 208 (estimated)
- Sponsor
- Bristol-Myers Squibb · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The purpose of this study is to evaluate the safety, tolerability, and exposure-response (E-R) of BMS-986435/MYK-224 in participants with symptomatic Heart Failure with Preserved Ejection Fraction (HFpEF).
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria
\- Adult participants with stable, symptomatic HFpEF with a normal heart pumping ability.
Exclusion Criteria
* Participants must not have a known diagnosis of obstructive or genetic hypertrophic cardiomyopathy or infiltrative/storage disorder such as cardiac amyloidosis, or any…
Contacts
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
855-907-3286
CONTACT
First line of the email MUST contain NCT # and Site #.
CONTACT